Form 4: Centessa Pharmaceuticals Acquisition Complete

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Summary

• Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company through a scheme of arrangement.
• The transaction, effective June 24, 2026, involved Eli Lilly's subsidiary, LDH XV Corporation, acquiring all outstanding ordinary shares.
• Shareholders are entitled to receive $38.00 in cash per ordinary share, plus a contingent value right (CVR) for potential additional payments up to $9.00 per share.
• The CVR payments are contingent upon the achievement of specified milestones.
• Restricted Share Units (RSUs) and share options were cancelled and converted into the right to receive cash consideration and CVRs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, providing a significant cash payout and potential for further upside through CVRs, although the CVRs introduce an element of uncertainty.

Positives

• Shareholders received a cash payment of $38.00 per ordinary share.
• Shareholders are eligible for potential future payments through contingent value rights (CVRs) of up to $9.00 per share.
• The acquisition provides a clear exit for shareholders and a definitive transaction for the company.

Negatives

• The acquisition means Centessa Pharmaceuticals plc will no longer be a publicly traded entity.
• The contingent value rights introduce uncertainty regarding future payments, as they depend on milestone achievement.

Risks

• The realization of contingent payments from the CVRs is dependent on Eli Lilly achieving specified milestones, which introduces uncertainty for former Centessa shareholders.
• Potential withholding taxes may reduce the net cash consideration received by shareholders.

Future Outlook

The future outlook for Centessa Pharmaceuticals as an independent entity is concluded due to the acquisition. For former shareholders, the outlook is tied to the achievement of milestones related to the contingent value rights.

Management Comments

• The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person.
• At the Effective Time, each outstanding and unvested RSU became fully vested, and at the Effective Time, each RSU was automatically cancelled and converted into the right to receive cash and a CVR.
• At the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive cash and a CVR.

Industry Context

StockSavvy.ai notes that this acquisition by a major pharmaceutical player like Eli Lilly signifies consolidation trends within the biopharmaceutical sector, often driven by strategic pipeline expansion or acquisition of promising assets.

Stakeholder Impact

• Shareholders: Receive $38.00 cash per share and a contingent value right (CVR) for potential additional payments.
• Employees: Their roles and future employment are now under Eli Lilly and Company.
• Creditors: Terms of existing debt and liabilities will be assumed or managed by Eli Lilly and Company.

Next Steps

• Shareholders will receive the cash consideration and contingent value rights as per the terms of the Scheme of Arrangement.
• Eli Lilly and Company will integrate Centessa Pharmaceuticals' assets and operations.

Key Dates

Recommendation

For existing shareholders, the acquisition provides a clear exit with a substantial cash component and potential upside. For potential new investors, the company is no longer independently traded, making a traditional 'buy' recommendation inapplicable. A 'hold' is appropriate for existing shareholders who may choose to wait for CVR milestone achievements, or 'sell' if they prefer immediate realization of value.

Keywords

Centessa Pharmaceuticals, Eli Lilly, Acquisition, Scheme of Arrangement, Form 4, SEC Filing, Contingent Value Rights, Ordinary Shares, Restricted Share Units, Share Options